Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)
July 4, 2019 updated by: GlaxoSmithKline
Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)
This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated into an Expanded Program on Immunization (EPI) regimen to infants living in sub-Saharan Africa.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Biological: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Biological: Engerix-B™ vaccine
- Biological: Infanrix/Hib™ vaccine
- Biological: Polio Sabin™ vaccine
- Biological: Rotarix™ vaccine
- Biological: Synflorix™ vaccine
- Biological: Measles vaccine
- Biological: Yellow fever vaccine
Study Type
Interventional
Enrollment (Actual)
705
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ouagadougou 01, Burkina Faso
- GSK Investigational Site
-
-
-
-
-
Kumasi, Ghana
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 2 months (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
All subjects must satisfy ALL the following criteria at study entry:
- A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
- Signed or thumb-printed informed consent obtained from the parent(s)/Legally Acceptable Representative [LAR(s)] of the child. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by an independent witness
- Subjects who the investigator believes that their parent(s)/LAR(s) can and will comply with the requirements of the protocol
- Healthy subjects as established by medical history and clinical examination before entering into the study
- Born to a mother who is Hepatitis B surface antigen (HBsAg) negative
- Born to a mother who is Human Immunodeficiency Virus (HIV) negative
- Born after a normal gestation period of 36 to 42 weeks inclusive.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:
- Child in care
- Acute disease and/or fever at the time of enrolment
- Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests
- Laboratory screening tests out of range
- Previous vaccination with diphtheria, tetanus, pertussis, Haemophilus influenzae type b, Streptococcus pneumoniae, hepatitis B vaccine or rotavirus vaccines.
- Planned administration/administration of a licensed vaccine not foreseen by the study protocol within 7 days of the first dose of study vaccine.
- Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Administration of immunoglobulins and/or any blood products in the period between birth and Dose 1 and within the three months preceding planned vaccine administration during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs in the period between birth and Dose 1.
- Concurrently participating in another clinical study at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Same sex twin
- Maternal death
- History of allergic reactions or anaphylaxis to previous immunizations.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
- Any other findings that the investigator feels would result in data collected being incomplete or of poor quality.
- Previous participation in any other malaria vaccine trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: RTS,S Regimen A Lot 1 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation.
This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen A Lot 2 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation.
This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10.
In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen A Lot 3 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation.
This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen B Lot 1 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation.
This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen B Lot 2 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation.
This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen B Lot 3 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation.
This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen C Lot 1 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation.
This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen C Lot 2 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation.
This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
EXPERIMENTAL: RTS,S Regimen C Lot 3 Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation.
This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
ACTIVE_COMPARATOR: Engerix B Regimen A Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
|
ACTIVE_COMPARATOR: Engerix B Regimen B Group
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10.
Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50.
Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally.
The measles and yellow fever vaccines were administered IM in the deltoid.
|
Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection.
Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Seroprotected Subjects Against Anti-Hepatitis B (HBs) Antigen
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
A seroprotected subject was defined as a subject with anti-HBs antibody titers greater than or equal to (>=) the cut-off of 10 mili-international units per mililiter (mIU/mL).
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis, with study groups pooled by primary vaccine administered (RTS,S vs Engerix -B).
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-Hepatitis B (HBs) Antibody Concentrations for RTS,S Group and Engerix B Group
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL.
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis, with study groups pooled by primary vaccine administered (RTS,S vs Engerix-B).
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-Hepatitis B (HBs) Antibody Concentrations for All Study Groups
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL.
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis, for each RTS,S Regimen A, B, C and each Engerix B Regimen A and B study groups.
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anti-Hepatitis B (HBs) Antibody Concentrations at Month 3
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL.
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis. Results presented are for the study groups receiving the RTS,S vaccine, pooled by vaccine lot, that is, for the RTS,S Lot 1, RTS,S Lot 2, and RTS,S Lot 3 groups, as defined below.
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-Hepatitis B (HBs) Antibody Concentrations at Month 14 and 26
Time Frame: At Months 14 and 26, aka at 12 and 24 months post Dose 3 of RTS,S vaccine or Engerix-B
|
Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL.
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis. Results presented are for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Months 14 and 26, aka at 12 and 24 months post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-Hepatitis B (HBs) Antibody Concentrations at Month 38, 50 and 51
Time Frame: At Months 38, 50 and 51, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B and one month post the Month 50 booster dose of Engerix-B
|
Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL.
A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).
The table shows updated results following partial or complete retesting/reanalysis. Results presented are for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Months 38, 50 and 51, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B and one month post the Month 50 booster dose of Engerix-B
|
|
Concentrations of Antibodies to the Hepatitis B RF1 Surface Antigen (Anti-HBs RF1) at Month 3
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Anti-HBs RF1 antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 33 EL.U/mL.
The table shows results for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Concentrations of Antibodies to the Hepatitis B RF1 Surface Antigen (Anti-HBs RF1) at Month 51
Time Frame: At Month 51, aka one month post the Month 50 booster dose of Engerix-B
|
Anti-HBs RF1 antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 33 EL.U/mL.
The table shows results for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Month 51, aka one month post the Month 50 booster dose of Engerix-B
|
|
Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 3
Time Frame: At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 0.5 EL.U/mL.
The table shows results for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 14
Time Frame: At Month 14, aka at 12 months post Dose 3 of RTS,S vaccine or Engerix-B
|
Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 0.5 EL.U/mL.
The table shows results for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
No anti-CS results are available for the time point 24 months post Dose 3 (Month 26) because the quantity of serum available for the anti-CS assay was insufficient for many samples.
|
At Month 14, aka at 12 months post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Anti-circumsporozoite Protein (Anti-CS) Antibody Concentrations at Month 38 and 50
Time Frame: At Months 38 and 50, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B
|
Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL).
The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 1.9 EL.U/mL.
The table shows results for each RTS,S Regimen A, B & C, and for each Engerix B Regimen A & B study groups.
|
At Months 38 and 50, aka 36 and 48 months post Dose 3 of RTS,S vaccine or Engerix-B
|
|
Pneumococcal Antibody Concentrations Against Synflorix Pneumococcal Vaccine Serotypes at Month 3
Time Frame: At Month 3, aka at one month post Dose 3 of Synflorix
|
Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), and expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL).
The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
The cut-off of the assay, by GSK assay, was greater than or equal to (>=) 0.2 µg/mL.
This corresponds to the standard ELISA value of 0.35 μg/mL.
This outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups.
|
At Month 3, aka at one month post Dose 3 of Synflorix
|
|
Pneumococcal Antibody Concentrations Against Synflorix Pneumococcal Vaccine Serotypes at Month 17
Time Frame: At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
Antibody concentrations were measured by GSK assay, and expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL).
The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
The cut-off of the assay, by GSK assay, was greater than or equal to (>=) 0.2 μg/mL.
This corresponds to the standard ELISA value of 0.35 μg/mL.
This outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix.
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups.
|
At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
|
Titers for Opsonophagocytic Activity Against Synflorix Pneumococcal Vaccine Serotypes at Month 3
Time Frame: At Month 3, aka at one month (1M) post Dose 3 of Synflorix
|
The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Streptococcus pneumoniae opsonophagocytic activity was presented as the dilution of serum (opsonic titer) able to sustain 50 % killing of live pneumococci under the assay conditions, expressed as geometric mean titers (GMTs).
The cut-off of the assay was an opsonic dilution >= 8.
This outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups.
|
At Month 3, aka at one month (1M) post Dose 3 of Synflorix
|
|
Titers for Opsonophagocytic Activity Against Synflorix Pneumococcal Vaccine Serotypes at Month 17
Time Frame: At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
The pneumococcal vaccine serotypes assessed were the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
Streptococcus pneumoniae opsonophagocytic activity was presented as the dilution of serum (opsonic titer) able to sustain 50 % killing of live pneumococci under the assay conditions, expressed as geometric mean titers (GMTs).
The cut-off of the assay was an opsonic dilution >= 8.
This outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix .
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups.
|
At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
|
Anti-protein D (PD) Antibody Concentrations at Month 3
Time Frame: At Month 3, aka at one month post Dose 3 of Synflorix
|
Anti-PD antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U/mL).
The cut-off of the assay was the seropositivity cut-off value of greater than or equal to 100 EL.U/mL.
This outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Synflorix.
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix-B Regimen A groups.
|
At Month 3, aka at one month post Dose 3 of Synflorix
|
|
Anti-protein D (PD) Antibody Concentrations at Month 17
Time Frame: At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
Anti-PD antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U/mL).
The cut-off of the assay was the seropositivity cut-off value of greater than or equal to 100 EL.U/mL.
This outcome concerns the subjects who received the RTS,S or Engerix -B vaccine co-administered with Synflorix.
Results presented are for the study groups pooled by co-administration, that is, for the RTS,S Regimen A and Engerix -B Regimen A groups.
|
At Month 17, aka one month post the Month 16 booster dose of Synflorix
|
|
Concentrations of Antibodies Against Acellular B-pertussis (BPT) at Day 0 and at Month 3
Time Frame: At Day 0 and at Month 3 (one month post Dose 3 of Infanrix-Hib)
|
The antibodies against BPT assessed were against pertussis toxoid (anti-PT), against filamentous haemagglutinin (anti-FHA), and against pertactin (anti-PRN).
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs), in ELISA units per milliliter (EL.U/mL).
The cut-off of the assay was the seropositivity cut-off value of greater than or equal to (>=) 5 EL.U/mL.
The table shows results for study groups pooled by primary vaccine administered (RTS,S vs Engerix -B)
|
At Day 0 and at Month 3 (one month post Dose 3 of Infanrix-Hib)
|
|
Anti-Rotavirus (Anti-RV) Antibody Concentrations
Time Frame: At Month 3, aka one month post Dose 2 of Rotarix
|
Anti-Rotavirus (anti-RV) antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).
The cut-off of the assay was the seropositive cut-off value of greater than or equal to (>=) 20 units per milliliter (U/mL).
This outcome measure was assessed in subjects who were administered Rotarix as part of an EPI regimen, with and without RTS,S vaccine co-administration.
This outcome concerns the subjects who received the RTS,S or Engerix-B vaccine co-administered with Rotarix.
Results presented are for the study groups pooled by RTS,S or Engerix-B vaccine co-administration, that is, for the RTS,S Regimen B and Engerix-B Regimen B groups.
|
At Month 3, aka one month post Dose 2 of Rotarix
|
|
Number of Subjects With Solicited Local Symptoms
Time Frame: Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine
|
Assessed solicited local symptoms were pain, redness and swelling at the site of injection.
All solicited local symptoms assessed were considered by the investigator as causally related to the study vaccination.
Analysis for this outcome was performed solely for the 7-days follow-up periods following the primary vaccination with RTS,S vaccine or Engerix-B (at Day 0, and Months 1 and 2).
Data presented are those for any occurrence of the assessed solicited local symptoms, that is, the occurrences of these symptoms regardless of their intensity grade.
|
Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine
|
|
Number of Subjects With Solicited General Symptoms
Time Frame: Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine
|
Assessed solicited general symptoms were fever, irritability/fussiness, drowsiness, and loss of appetite.
Fever was defined as axillary temperature higher than (>) 37.5 degrees Celsius (°C).
Analysis for this outcome was performed solely for the 7-days follow-up periods following the primary vaccination with RTS,S vaccine or Engerix-B (at Day 0, and Months 1 and 2).
Data presented are those for any occurrence of the assessed solicited general symptoms, that is, the occurrences of these symptoms regardless of their intensity grade or relationship to vaccination.
|
Within the 7-day follow-up period (Days 0-6) after administration of Dose (D) 1, 2 and 3, respectively, with RTS,S or Engerix-B vaccine
|
|
Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 to Month 8
Time Frame: From Day 0 to Month 8
|
A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.
IMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison's disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis.
|
From Day 0 to Month 8
|
|
Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 to Month 26
Time Frame: From Day 0 to Month 26
|
A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.
IMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison's disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis.
|
From Day 0 to Month 26
|
|
Number of Subjects With Potential Immune Mediated Disorders (pIMDs) From Day 0 up to Study End (Month 51)
Time Frame: From Day 0 up to Study End (Month 51)
|
A potential immune mediated disorder (pIMD) was defined as an event about which concerns arose that vaccination may have interfered with immunological self-tolerance of the subjects.
IMDs assessed included among others neuroinflammatory disorders (such as optic neuritis, multiple sclerosis, or encephalitis), musculoskeletal disorders (such as cutaneous lupus, rheumatoid arthritis, juvenile arthritis, or psoriatic arthropathy), gastrointestinal disorders (ulcerative colitis and ulcerative proctitis, celiac disease), metabolic diseases (such as autoimmune thyroiditis, or diabetes Mellitus Type 1, Addison's disease), skin disorders (such as psoriasis or vitiligo), and other disorders such as vasculitis, pernicious anemia, or, sarcoidosis.
|
From Day 0 up to Study End (Month 51)
|
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Time Frame: Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B
|
An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B
|
|
Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) Within the 30-day Follow-up Periods (Days 0-29)
Time Frame: Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B
|
A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.
A fatal SAE was defined as a SAE resulting in the death of the study subject.
|
Within the 30-day follow-up periods (Days 0-29) after vaccination with RTS,S vaccine or Engerix-B
|
|
Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) From Day 0 to Month 8
Time Frame: From Day 0 to Month 8
|
A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.
A fatal SAE was defined as a SAE resulting in the death of the study subject.
|
From Day 0 to Month 8
|
|
Number of Subjects With Any and Fatal Serious Adverse Events (SAEs) From Day 0 to Month 26
Time Frame: From Day 0 to Month 26
|
A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.
A fatal SAE was defined as a SAE resulting in the death of the study subject.
|
From Day 0 to Month 26
|
|
Number of Subjects With Any, Fatal and Related Serious Adverse Events (SAEs) From Day 0 up to Study End (Month 51)
Time Frame: From Day 0 up to Study End (Month 51)
|
A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or a reported adverse event of specific interest such as seizures occurring within a 30-day period of vaccination, immune-mediated disorders, and specific autoimmune diseases.
A fatal SAE was defined as a SAE resulting in the death of the study subject.
A related SAE was defined as a SAE assessed by the investigator as being causally related to vaccination.
|
From Day 0 up to Study End (Month 51)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 17, 2011
Primary Completion (ACTUAL)
January 9, 2013
Study Completion (ACTUAL)
February 9, 2017
Study Registration Dates
First Submitted
April 28, 2011
First Submitted That Met QC Criteria
April 28, 2011
First Posted (ESTIMATE)
May 2, 2011
Study Record Updates
Last Update Posted (ACTUAL)
July 18, 2019
Last Update Submitted That Met QC Criteria
July 4, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Vector Borne Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Parasitic Diseases
- Protozoan Infections
- Hepatitis B
- Hepatitis
- Malaria
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- 113681
- 2011-001508-37 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD is available via the Clinical Study Data Request site (click on the link provided below).
IPD Sharing Time Frame
IPD is available via the Clinical Study Data Request site (click on the link provided below)
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
Medicines for Malaria VentureSwiss Tropical & Public Health Institute; Rinda Ubuzima, Rwanda; Swiss BioQuant; ACE ResearchNot yet recruitingMalaria | Malaria Infection | Malaria Prophylaxis | Malaria (Plasmodium Falciparum) | Malaria Falciparum | Malaria Parasitaemia | Malaria PreventionRwanda
-
Noguchi Memorial Institute for Medical ResearchMedical Research Center Unit The Gambia (MRCG)RecruitingMalaria Infection | Malaria Asymptomatic Parasitaemia | Malaria Falciparum | Malaria TransmissionGhana
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsWithdrawnPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLaos
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
-
GlaxoSmithKlineThe PATH Malaria Vaccine Initiative (MVI)Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCrucell Holland BV; The PATH Malaria Vaccine Initiative (MVI)Completed
-
GlaxoSmithKlineCompletedTuberculosisPhilippines
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedTuberculosis (TB) | Tuberculosis VaccinesSouth Africa
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted